

## pCODR Information Session for Patient Advocacy Groups

August 9, 2011

Hello,

The pan-Canadian Oncology Drug Review (pCODR) is a newly established evidence-based cancer drug review process, designed to bring consistency and clarity to the assessment of cancer drugs by looking at clinical evidence, cost-effectiveness and patient perspectives. The information that results from this process will be used to provide evidence-based recommendations to provinces and territories to guide their drug funding decisions.

We are inviting patient advocacy groups to attend an information session on September 9, 2011 at the Cosmopolitan Hotel, 8 Colborne Street in Toronto, from 10:00 a.m. to noon in the Chi meeting room. For those unable to join in-person, a webinar option will be provided.

The objectives of the information session are to:

- provide an overview of the pCODR process
- to explain how patient advocacy groups can provide input on a drug submission to pCODR

We will not be discussing any particular drug nor are we in a position to offer advice on drug access. Your provincial cancer care program should be able to answer questions of this nature. The contributions of patient advocacy groups have been invaluable in shaping the pCODR process.

We hope you will be able to join us at this information session. Please confirm your attendance at the information session via e-mail: [rsvp@pcodr.ca](mailto:rsvp@pcodr.ca) by September 2, 2011.